Replies to post #124996 on Biotech Values

[DewDiligence]

ACHN thinks a PI + NS5A inhibitor alone may be sufficient for durable SVR in HCV genotype 1b patients, as opposed to 1a.

I haven’t heard that before. Were they referring to their own drugs, specifically, or to the PI and NS5A classes in general?